TRex Bio is a biotechnology company focused on mapping human tissue immunobiology to identify therapeutics for immune-mediated diseases. They leverage a Deep Biology Platform to map regulatory T cell (Treg) behavior in human tissue and link dysregulation to disease. By combining high-throughput sequencing, computational tools, and disease-relevant human assays, they develop tissue-focused, first-in-class therapeutics aimed at restoring tissue homeostasis. The company emphasizes translational immunology and collaborative drug discovery to address inflammatory and autoimmune conditions.